82.51
+0.38(+0.46%)
Currency In USD
Address
15440 Laguna Canyon Road
Irvine, CA 92618
United States of America
Phone
949 409 9820
Website
Sector
Healthcare
Industry
Biotechnology
Employees
323
First IPO Date
October 16, 2020
| Name | Title | Pay | Year Born |
| Bobak R. Azamian | Co-Founder, President, Chief Executive Officer & Chairman | 1.26M | N/A |
| Elizabeth Yeu | Chief Medical Officer | 156,691 | 1978 |
| Bryan Wahl | General Counsel & Corporate Secretary | 619,087 | 1978 |
| Aziz Mottiwala | Chief Commercial Officer | 836,505 | 1978 |
| Seshadri Neervannan | Chief Operating Officer | 892,332 | 1968 |
| Jeffrey S. Farrow | Chief Financial Officer & Chief Strategy Officer | 930,569 | 1962 |
| David Nakasone | Head of Investor Relations | 0 | N/A |
| Matthew Rossen | Vice President of Marketing | 0 | 1978 |
| Scott Youmans | Vice President of Sales | 0 | N/A |
| Adrienne Kemp | Senior Director of Corporate Communications | 0 | N/A |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
